A similar decision for Romo is being made by Amgen. JnJ dropped their IL-6 because of more time and cost. Amgen is being asked the same thing so the question is whether the delay will and lower product revenue be worth the time and cost or is Amgen better off using that investment in other areas like M&A.
“We maintain our belief in the efficacy and safety of sirukumab, an anti-IL-6 monoclonal antibody. However, the need for additional clinical data would result in significant delays to patient access in parts of the world. Given this, as well as the availability of other treatments targeting the IL-6 pathway, Janssen has made a strategic decision to prioritize other assets in our portfolio.”
“We maintain our belief in the efficacy and safety of sirukumab, an anti-IL-6 monoclonal antibody. However, the need for additional clinical data would result in significant delays to patient access in parts of the world. Given this, as well as the availability of other treatments targeting the IL-6 pathway, Janssen has made a strategic decision to prioritize other assets in our portfolio.”